Search
Research
Safety, tolerability, and immunogenicity of V114 pneumococcal vaccine compared with PCV13 in a 2+1 regimen in healthy infants: A phase III study (PNEU-PED-EU-2)This phase III study evaluated safety, tolerability, and immunogenicity of V114 (15-valent pneumococcal conjugate vaccine) in healthy infants. V114 contains all 13 serotypes in PCV13 and additional serotypes 22F and 33F.
Research
Factors influencing scar formation following Bacille Calmette-Guérin (BCG) vaccinationThe prevalence of scar formation following Bacille Calmette-GuĂ©rin (BCG) vaccination varies globally. The beneficial off-target effects of BCG are proposed to be stronger amongst children who develop a BCG scar. Within an international randomised trial ('BCG vaccination to reduce the impact of coronavirus disease 2019 (COVID-19) in healthcare workers'; BRACE Trial), this nested prospective cohort study assessed the prevalence of and factors influencing scar formation, as well as participant perception of BCG scarring 12 months following vaccination.
Research
Modalities of group A streptococcal prevention and treatment and their economic justificationInfection by group A Streptococcus (Strep A) results in a diverse range of clinical conditions, including pharyngitis, impetigo, cellulitis, necrotising fasciitis, and rheumatic heart disease. In this article, we outline the recommended strategies for Strep A treatment and prevention and review the literature for economic evaluations of competing treatment and prevention strategies.
Research
Core protocol for the adaptive Platform Trial In COVID-19 Vaccine priming and BOOsting (PICOBOO)The need for coronavirus 2019 (COVID-19) vaccination in different age groups and populations is a subject of great uncertainty and an ongoing global debate. Critical knowledge gaps regarding COVID-19 vaccination include the duration of protection offered by different priming and booster vaccination regimens in different populations, including homologous or heterologous schedules.
Research
Real world impact of 13vPCV in preventing invasive pneumococcal pneumonia in Australian children: A national studyWe aimed to assess the direct protective effect of 13 valent pneumococcal conjugate vaccine (13vPCV) against invasive pneumococcal pneumonia (IPP; including pneumonia and empyema) in children using a nation-wide case-control study across 11 paediatric tertiary hospitals in Australia.
Research
Effectiveness of 7-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease in Medically At-Risk Children in Australia: A Record Linkage StudyChildren with chronic medical conditions are at higher risk of invasive pneumococcal disease (IPD), but little is known about the effectiveness of the primary course of pneumococcal conjugate vaccine (PCV) in these children.
Research
Immunisation and pregnancy - who, what, when and why?Recommending vaccination to pregnant women is important as evidence shows they are more likely to get vaccinated if their healthcare provider advises it
Research
Meningococcal serogroup B-specific responses after vaccination with bivalent rLP2086Assessment of the persistence of bactericidal antibodies up to 4 years after a three-dose schedule of bivalent rLP2086
Research
Influenza epidemiology, vaccine coverage and vaccine effectiveness in children admitted to sentinel Australian hospitals in 2014The Influenza Complications Alert Network (FluCAN) is a sentinel hospital-based surveillance programme operating in all states and territories in Australia
Research
Efficacy of human papillomavirus 16 and 18 vaccine against cervical cancer: Final randomized, double-blind PATRICIA trialWe report final event-driven analysis data on the immunogenicity and efficacy of the human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine in...